In a major twist that could potentially result in as much as $1B for equitable PrEP access in the US, the government has just made the decision to appeal last year’s jury verdict in the US v. Gilead case. The Choice Agenda and PrEP4All discussed the origin of US v. Gilead, the reasons for the government appeal, and what the case means for PrEP users in the United States.
PrEP Justice
Updates on the US v. Gilead case and the fight for equitable PrEP access
GPP Body of Evidence Webinar Series
Good Participatory Practice Guidelines have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
However, GPP implementation is far from easy—it looks different in every context, outcomes can be difficult to quantify, engagement work is often seen as secondary to clinical processes, and therefore, undervalued and under-resourced.
To help solve for this, last year AVAC introduced the GPP Body of Evidence, a new resource that brings together a set of tools highlighting the value of GPP, as well as the nuts and bolts of how to get it done.
Now join us for a series of webinars in collaboration with The Global Health Network, Wellcome Trust, and WHO, to analyze the current state of GPP and discuss areas of growth and further development as we chart the way forward.
It’s Not Just about the Trial: GPP from discovery to delivery in TB research
GPP enhances every stage of the research lifecycle. In this webinar, our partners at TB Alliance, SMART4TB, and THINK will shared experiences, lessons learned, and innovative approaches in integrating GPP at the organizational, network and situational level, from drug development through delivery.
Moderators:
- Stacey Hannah, AVAC
- Dr. Michele Tameris, University of Cape Town
Panelists:
- Stephanie Seidel, TB Alliance
- Erica Lessem, SMART4TB
- Masingita Lambane, THINK
Recording / Stephanie Seidel Slides / Erica Lessem Slides / Masingita Lambane Slides
The GPP Body of Evidence: GPP Monitoring and Evaluation Frameworks, REAL and REAL2
GPP is an essential part of clinical trials research, and an ethical imperative to creating equitable and effective clinical trials. GPP is created by and for communities, so it necessarily looks different and takes multiple forms in different cultural contexts. This kind of responsiveness is inherent to GPP, but it also makes it difficult to measure and evaluate.
In this webinar, we learned from the Realist Review of Community Engagement and the REAL2 review of participatory research that both examined frameworks for evaluating community engagement efforts, as well as the Global Health Network’s new course on evaluation, and other evaluation efforts in the field of GPP.
Moderator:
- Jessica Salzwedel, AVAC
Panelists:
- Alun Davies, The Global Health Network
- Sassy Molyneux, KEMRI-Wellcome Trust
- Dr. Robin Vincent, Oxford University
Recording / Alun Davies Slides / Sassy Molyneux Slides / Dr. Robin Vincent Slides
The More We Know
Evolving our understanding of PrEP for cisgender women
Science and real-world experience continue to demand a re-assessment of our collective understanding of the safety and effectiveness of PrEP options for women, including oral, vaginal ring, and injectable options. For instance, a new paper in the Journal of the American Medical Association by Dr. Jeanne Marrazzo (HIV Pre-Exposure Prophylaxis with Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women) challenges the notion, baked into policies, programs and “conventional wisdom”, that cisgender women need to be “super-adherers” to achieve protection utilizing oral PrEP. In this webinar, we discussed this important paper and more.
Speakers:
• Dr. Jeanne Marrazzo, National Institute of Allergy and Infectious Diseases
• Joyce Ng’ang’a, WACI Health
Moderator:
Raniyah Copeland, Equity & Impact Solutions
Materials:
Recording / Ukrainian Audio / Slides / Resources / Audio Transcript (English/Ukrainian)
AVAC in Conversation with NIAID’s Jeanne Marrazzo
The new director of National Institute of Allergy and Infectious Diseases (NIAID), Dr. Jeanne Marrazzo joined AVAC Executive Director in conversation.
HIV Cure and the Environment
How location informs cure research
AVAC and REACH for the Cure hosted a webinar to discuss how the environment may impact HIV cure strategies. During this webinar, both organizations explored how clades, co-infections, early treatment, and other factors can help inform existing approaches to HIV cure research. Dr. Adam Ward of Weill Cornell Medicine shared the latest data followed by an informal conversation.
African Civil Society Mobilization for PEPFAR Reauthorization
Tuesday, November 28 at 7:00 AM ET
Moderator: Richard Muko, Regional Implementation Advocacy Manager, AVAC
Panelists: Joan Chamungu, Tanzanian Network of Women Living with HIV, Lawrence Khonyongwa, Malawi Network of People of Living with HIV, TBC, African Network of Youth Living with HIV, Annette Gaudino, Advocacy Coalition Manager, GAPP
Hosted by African Network of Youth Living with HIV (AY+), East African Network of AIDS Serving Organizations (EANNASO), Key Populations Trans-National Collaboration (KPTNC) and Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS)
Join civil society organizations in PEPFAR recipient countries to discuss the status and political context of the current reauthorization and mobilize to call on the US Congress to recommit this life sustaining program. Bring your questions and please share this invitation widely in your relevant networks.
Pandemic Accord Briefing for Civil Society & Community Partners
The Pandemic Accord negotiations are ongoing, and should come to fruition next year. What do they mean for your work, your country, and the future of global health?
On Tuesday, November 21, 8:00 to 9:30 AM EST / 2:00 to 3:30 PM CEST, advocates came together to discuss two years of talks and what’s next to progress global health equity.
Spotlight on New PrEP Tools and Data: From R&D to access
Tuesday, November 28
Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Staying on top of the latest advances is key for advocates, researchers, funders, and others working in HIV prevention to do their job effectively—but how can you navigate the vast amount of PrEP data online? AVAC, the Medicines Patent Pool (MPP), and Unitaid presented information on three important online PrEP resources and understand how they can support and enhance your work:
- PrEPWatch.org: the one stop shop for PrEP resources to support introduction and scale-up, including the PrEPTracker, the only place to find information on global PrEP initiations online
- Long Acting Therapeutics Patents and Licenses Database (LAPaL): LAPaL is the go-to resource to learn about long-acting therapeutics, their patent landscape, development and regulatory status
- Access to Medicines Tracker: the go-to place for quarterly-updated insights on regulatory filings, regulatory approvals, and product supplies of MPP-licensed generic medicines at the country level.
Let’s Talk About HIV Cure Research: An introduction to the science under investigation
Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board hosted a webinar on November 15 to review the current state of HIV cure research. This webinar explored what makes curing HIV so challenging, the strategies being pursued, and what is happening in locally in NYC!
HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South
November 15, 10:00 to 11:30 AM ET
The Choice Agenda and partners hosted a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096 on November 15. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Visit the study website here.
Speakers (list in formation):
Prof. LaRon E. Nelson. Yale School of Nursing; HPTN 096 Protocol Co-Chair
Christopher Hucks-Ortiz, HPTN Black Caucus Chair
Dr. Cedric Pulliam, HPTN 096 Community Strategy Group
Abraham Johnson, HPTN 096 Research Advisor
Moderators:
Riko Boone, Treatment Action Group
John Meade, AVAC
Co-sponsored by PrEP in Black America and Federal AIDS Policy Partnership Research Working Group